Health Care · Life Sciences Tools & Services

Thermo Fisher Scientific Inc TMO

$617.10-5.08 (-0.82%)delayed quote · as of 2026-09-01 02:49 UTC

Open TMO in the workspaceCharts, statements, and the evidence behind every figure — free to start.

Market cap

$228.2B

Previous close

$622.18

Volume

1.4M

52-week range

$435.27 – $647.00

Verdict

Reading TMO’s filed statements…

Continue with TMO in ALAN

Full evidence trail, financial statements back a decade, valuation history, charts, and alerts.

Open in the workspace Create free account

For information and research only. Not investment advice. ALAN does not place trades or execute orders. Figures come from the sources shown and can lag the market; verify independently before making decisions. Past performance is not predictive of future results.

Health Care · Life Sciences Tools & Services

Thermo Fisher Scientific Inc TMO

$617.10-5.08 (-0.82%)delayed quote · as of 2026-09-01 02:49 UTC

Open TMO in the workspaceCharts, statements, and the evidence behind every figure — free to start.

Market cap

$228.2B

Previous close

$622.18

Volume

1.4M

52-week range

$435.27 – $647.00

Verdictconfidence 100% · high

Momentum stands out; value and growth flash caution.

3 of 5 dimensions score well; value and growth flash caution.

Value402/5 checks

Growth402/5 checks

Execution603/5 checks

Health603/5 checks

Momentum804/5 checks

Fair-value estimate $339.38 per share (2-stage FCF · individual beta · 10Y Rf 4.7% · term g 2.75% blended 50/50 with 15x earnings anchor) — the price sits 82% above it.

Every check behind these scores — with its numbers, source, and evidence link — is in the workspace. Free account required.

Key ratioslatest filing FY 2025

Value

P/E TTM

33.2

P/E FWD

22.4

EV/EBITDA TTM

28.0

PEG

1.53

FCF yield TTM

3.2%

Growth

Revenue 3y

−0.3%/yr

Revenue YoY

+3.9%

Expected EPS

+48.1%

Execution

Piotroski F

6 / 9

ROIC

19.1%

Gross margin

—

Health

Altman Z

3.94

Current ratio

1.89

Debt/equity

0.80

Momentum

vs 50-day

+21.3%

vs 200-day

+18.5%

52-wk range

86%

FY 2025: revenue $44.6B · net income $6.7B · free cash flow $6.3B (SEC EDGAR filings)

ALAN GLOBAL INTELLIGENCE · alanglobalintelligence.comquote as of 2026-09-01 02:49 UTC · fundamentals FY 2025 · SEC EDGAR

Verdict

Reading TMO’s filed statements…

Continue with TMO in ALAN

Full evidence trail, financial statements back a decade, valuation history, charts, and alerts.

Open in the workspace Create free account